Goldman Sachs reiterates its Buy rating on CVS Caremark CVS and raises its price target from $43 to $44 per share as the company paints a consistent and upbeat picture.
Goldman Sachs notes, "We remain Buy-rated on CVS as its positioning and execution continue to improve, and it offers up a perfect fit for today's large-cap investor wishlist: a predictable operating algorithm and disciplined capital allocation. We raise our 12m PT by $1, to $44, on estimate hikes (on a lower tax rate)."
CVS closed at $40.46 per share on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in